Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ: DRMA )

1.220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.220
Bid (Size) 1.200 (3)
Ask (Size) 1.300 (13)
Prev. Close 1.220
Today's Range 1.220 - 1.220
52wk Range 1.000 - 6.666
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
Dermata to Present on BioPub on January 31, 2025
Via ACCESS Newswire

Performance

YTD
-12.23%
-12.23%
1 Month
+8.93%
+8.93%
3 Month
-4.69%
-4.69%
6 Month
-22.29%
-22.29%
1 Year
-80.41%
-80.41%

More News

Read More
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
Via ACCESS Newswire
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Via ACCESSWIRE
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Via ACCESSWIRE
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
From Virtual Investor Conferences
Via GlobeNewswire
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Peering Into Dermata Therapeutics's Recent Short Interest
Via Benzinga
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
Via Benzinga
Topics Stocks
Exposures US Equities
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Via ACCESSWIRE
Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024
Via InvestorPlace
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Dermata Therapeutics Shares Are Trading Over 100%: What You Need To Know
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.